![David N. Judelson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David N. Judelson
No más puestos en curso
Perfil
David N.
Judelson is a Co-Founder of Biopure Corp.
and has been Vice Chairman since 1984.
He is a Co-Founder and Chairman of Digital Compression Technology LP.
He co-founded Gulf and Western Industries, Inc. in 1956 and was President and Chief Operating Officer from 1967 to 1983.
Mr. Judelson received a Bachelor of Mechanical Engineering degree from New York University College of Engineering.
Antiguos cargos conocidos de David N. Judelson.
Empresas | Cargo | Fin |
---|---|---|
Digital Compression Technology LP | Presidente | 17/09/2018 |
Biopure Corp.
![]() Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Fundador | - |
Formación de David N. Judelson.
New York University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Biopure Corp.
![]() Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Health Technology |
Digital Compression Technology LP |
- Bolsa de valores
- Insiders
- David N. Judelson